Evolving value to account for disruptive clinical products

Improving the value assessment process for life science organizations
Published - December 2022 • 10-min read

With the impending influx of disruptive products like cell and gene therapies, stakeholders must rethink how they assess medical value—*and how that differs from the way we think of legacy products.*

Innovative and disruptive products create new challenges not only for value assessment, but also for who will be responsible for achieving and monitoring outcomes. Additionally, how all stakeholders think about value is changing. Notably, the importance of representation and diversity in clinical trials has increased due to societal and cultural forces that go beyond the benefits of more representative data and the existence of health disparities.

Something that these new products won't change is the impossibility in aligning all stakeholders on a single definition of value, however, we have identified three key areas where change is both necessary and possible.
# Table of contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>The conventional wisdom</td>
<td>3</td>
</tr>
<tr>
<td>Our take</td>
<td>5</td>
</tr>
<tr>
<td>Three imperatives to improve your value assessment framework</td>
<td>6</td>
</tr>
<tr>
<td>1. Expand frameworks to account for broader member and population</td>
<td>7</td>
</tr>
<tr>
<td>considerations</td>
<td></td>
</tr>
<tr>
<td>2. Seek input from non-traditional perspectives and partner externally</td>
<td>9</td>
</tr>
<tr>
<td>3. Monitor and track outcomes to align value endpoints to meaningful</td>
<td>13</td>
</tr>
<tr>
<td>time horizons</td>
<td></td>
</tr>
<tr>
<td>Parting thoughts</td>
<td>16</td>
</tr>
<tr>
<td>Related content</td>
<td>17</td>
</tr>
</tbody>
</table>
The conventional wisdom

Defining health care value is tricky, especially when there is no shared consensus of benefits and costs and the lack of a single 'decider' to arbitrate the often-conflicting interests of stakeholders. One that that is clear is that today's approaches to value must evolve as new and impending products challenge the existing paradigm. Historically, health plans and prescribers relied on the limited set of randomized control trials (RCTs) used for FDA approval, along with a short-term cost over benefit calculation to determine whether a drug would provide value to a patient. Given the rising costs and substantial patient care implications of emerging, disruptive clinical products, relying on these metrics alone is no longer sufficient.

Moving forward, this will require life science organizations to forge a deeper understanding of how other stakeholders define benefits and costs and how that's evolving with new products.

A few of the common tensions in defining value as an outcome of treatment

\[
\text{Value} = \frac{\text{Benefit}}{\text{Cost}}
\]

- Clinical or financial benefit?
- Does societal benefit count? Patient preference?
- Benefit for whom - the patient or population?
- Total cost of care? Avoidable cost?
- Over what time horizon?
- Compared to what?
- Cost to whom?

The conventional wisdom

Exacerbating this need for a different approach to value is the pipeline of innovative products coming to market. For example, million-dollar drugs are gaining market approval without the decades of data necessary to definitively prove the durability of their positive impact.

A few examples of the common points of contention in defining value as an outcome of treatment are:

**The tradeoff between value for the patient and population** – Given concerns over total cost of care, decisions that may be optimal for individual patients would not be optimal when taking a population level approach and weighing the relative costs and benefits of treatment.

*Exemplar products: deep brain stimulation, ultra high-cost drugs.*

**Determining time horizons** – The price tags and reimbursement approaches for newer therapies create additional hurdles around the time horizon in which value is delivered. Many novel products require longitudinal and other data that goes beyond what is required by regulators and/or have benefits that accrue over a timeframe beyond the typical commercial health plan focus.

*Exemplar products: ultra high-cost drugs, digital therapeutics (DTx)*

**Increased lack of direct comparators** – The rise of non-pharmaceutical interventions is making it harder for life science organizations, manufacturers, payers, and regulators to compare across potential treatments.

*Exemplar products: digital therapeutics (DTx)*

**Identifying and quantifying avoided costs** – As diagnostics become more precise, this creates challenges to demonstrate return on investment (ROI).

*Exemplar products: pharmacogenomics and biomarker testing*
Our take

Because traditional treatment paradigms are being disrupted, life science stakeholders must take a more coordinated, expansive approach to data collection, evidence-generation, outcomes monitoring, and value assessment. Challenges such as high upfront costs of treatments, lack of comparators for first-in class and orphan drugs, reduced decision-making time due to FDA fast-tracking, and increased complexity of technologies and therapies signal that stakeholders need to take action.

To do so, they will need to ask new and different kinds of questions about data availability and integration. Additionally, they will need to think differently about study protocol designs to ensure recruitment of representative samples due to a potentially limited subject pool because of the nature of treatment. This will also require life science companies to consider how to collect real-world data, and find opportunities for support and profitability.

The role of life science organizations should be to find ways to partner with payers and HTAs in assessing value and finding common ground. Life science organizations should grapple with the following questions to start to establish a new paradigm and demonstrate value despite these challenges:

- How are we going to define value for our products, and how can we structure our value assessment framework to address unmet needs of patients?
- Which time horizons and endpoints best demonstrate value and impact? How does that vary by stakeholder?
- How do we align internal incentives to maximize the impact of our collective efforts?
- How can we take an ecosystem approach to thinking about evidence circulation and influence?
Three imperatives to improve your value assessment framework

Life science organizations are uniquely situated within the healthcare ecosystem due to their knowledge sharing and exchange of clinical insights across stakeholder groups and have an opportunity to improve processes across sectors to achieve medical value.

After speaking with leaders in this space, we’ve identified three imperatives for life science organizations to tailor and target their value assessment framework to account for disruptive clinical products:

01 IMPERATIVE
Expand frameworks to account for broader member and population considerations

02 IMPERATIVE
Seek input from non-traditional perspectives and partner externally

03 IMPERATIVE
Monitor and track outcomes to align value endpoints to meaningful time horizons

Source: Advisory Board interviews and analysis.
Expand value frameworks to account for broader patient and population considerations

It is imperative to expand value frameworks to catalyze more impactful evidence generation strategies, craft value narratives, and ultimately optimize patient outcomes. Life science organizations must shift from looking at one-time costs and immediate clinical outcomes to a broader set of value drivers to help payers approve products and create the optimal case for market adoption by appealing to endpoints that create value for both patients and providers. A broader set of value drivers includes the opportunity cost of not treating a patient, the overall impact on total cost of care, and patient preferences or quality of life. As critical as it is to get patients to the care they need, it’s even more important to ensure that the entire care pathway is accounted for in a holistic manner to determine the true benefit of a new clinical product.
1. EXPAND VALUE FRAMEWORKS TO ACCOUNT FOR BROADER MEMBER AND POPULATION CONSIDERATIONS (CONT.)

Life science leaders should be aiming to ensure data is transformed into evidence that meet both patient and population needs.

**Questions for life sciences leaders to consider:**

- What kinds of real-world evidence meaningfully inflect choices about product access and use?
- How do different “types” of payers weigh health economic data? What metrics beyond safety and efficacy have the greatest salience with different kinds of payers?
- What partnership models are payers willing to engage in to expand the time horizons they consider for value?
- When in the product lifecycle can changes in data collection and evidence generation create meaningful impacts on payer and provider perception of value?
Seek input from non-traditional perspectives and partner externally

Expanding the definition of an influencer

Because value means something different to each stakeholder, it is critical for life science organizations to understand a multitude of viewpoints so that they in turn can support the rest of the healthcare ecosystem in achieving medical value.

Life science leaders need to think beyond one source or channel of evidence dissemination and understand how different sources of information and influence interact. In the past, most targets of medical strategy have focused on key opinion leaders (KOLs) as “key influencers.” While KOLs remain an important part of information dissemination and clinical consensus, other influencers such as DOLs are increasingly able to change perceptions of products and companies. Some examples include:

- Health technology assessment organizations (HTAs)
- Digital opinion leaders (DOLs)
- Patient advocacy groups
- Economists
- Sociologists
- Physician groups
2. SEEK INPUT FROM NON-TRADITIONAL PERSPECTIVES AND DEPLOY INTEGRATED ASSESSMENT TEAMS (CONT.)

Because of this, non-traditional perspectives should be leveraged as these groups can be beneficial partners to life sciences organizations in the education and marketing for newer products, as well as data tracking.

Additionally, consulting a broader range of external stakeholders creates diverse insight generation. A parallel shift that is occurring is the shift from a model of evidence dissemination to one where it is vital to understand how evidence circulates to create medical consensus. Life science leaders generally should be taking an “ecosystem approach” to thinking about evidence circulation and influence by looking at social data, journals, blogs, conferences, etc. and mapping out the interplay of patients, physicians, and other influencers.

Questions for life sciences leaders to consider:

- How can life science leaders overcome the internal siloes with HEOR, regulatory and market access that limit the effectiveness of evidence generation to meet all customers’ demands?
- What communication tactics are most effective to translate insights from the field into product/TA strategy?
- What is the most effective way to disseminate field-based value stories throughout the entire organization?
- Which strategies for evidence dissemination (e.g. publications, conferences, office visits) are most effective to reach different providers archetypes (e.g., physicians, KOLs, risk-bearing providers?)
- How can you use conversations from online clinician communities to better understand HCPs’ uses and perceptions of your products as well as current evidence needs?
2. SEEK INPUT FROM NON-TRADITIONAL PERSPECTIVES AND DEPLOY INTEGRATED ASSESSMENT TEAMS (CONT.)

Designate teams to alleviate administrative burdens

Many stakeholder groups struggle to identify who is (or should be) responsible for capturing and tracking outcomes data. This challenge is made more complex as physicians are already burnt out and not reimbursed for the additional tasks of data collection, tracking patients, and providing back data. As health care leaders struggle with these challenges, they are increasingly looking to adopt risk-sharing finance models to create accountability for cohesive, patient-centered care delivery through value-based care.

Life science organizations must identify practical ways to partner externally, aggregate data, and incentivize its collection through designated teams. An example of this is Optum’s approach to alleviate payers’ data adjudication burden by outcomes-based programs. Third parties are responsible for verifying payers and providers, assessing patient health status across the care continuum, and identifying outcome events. Most notably, this program leverages claims and other clinical data to ensure understanding of outcomes and patient segments to create value for all stakeholders.

Snapshot of Optum’s outcomes-based contract program:
3rd party outcomes adjudication

Follow patient independent of health plan (not just UHC)

**PROInsight**
Cloud-based system …

Patient-reported outcomes (claims analytics, medical chart abstraction)

**Claims Analytics**

- HEOR expertise
- Experience with 20+ OBCs
- Analytics at scale

For capturing, managing and reporting PRO data

- Document clinical outcomes
- HEOR experts design chart abstraction protocol
- Leverage RQNS Operations / CIOX relationship for chart collection
2. SEEK INPUT FROM NON-TRADITIONAL PERSPECTIVES AND DEPLOY INTEGRATED ASSESSMENT TEAMS (CONT.)

Questions for life sciences leaders to consider:

- How can we streamline data management, analysis and use?
- How do we coordinate data requests and uses between internal organizations?
- How will we determine what the source of outcome data is, and in turn, which metrics to choose?
- How do we get stakeholders to not only accept outcomes-based contracting, but to accept the viability that comes with it?
- How should our data collection strategy adapt for market dynamics like site-of care shifts to gather the data necessary to provide localized insights?
Monitor and track outcomes to inform action

Payers, regulators, patients, and providers have different incentives and perspectives when it comes to measuring meaningful impact. For example, payers may argue that if a drug or therapeutic does not provide meaningful clinical improvement and reduction in health costs, that treatment is not beneficial while providers may feel that any change in a patient’s clinical pathway may be sufficient and justified, regardless of reduction in cost.

Life science leaders have a responsibility- and opportunity- to step in and incorporate alternative perspectives and directly have an impact on the availability and use of new medications by other stakeholders in the ecosystem.

Real world evidence (RWE), any evidence about a medical product or intervention that comes from outside of a clinical trial, provides insight into real-life treatment outcomes and can offer a more accurate representation about how medical products and interventions work for different patient populations. RWE will be vital to life science leaders’ success in demonstrating product value and aligning on time horizons. Because many new products pose a challenge to randomized controlled trials (often due to niche populations, small trial pools/limited trial participants, and ethical concerns over the use of placebos), life science organizations should continuously evaluate clinical products post-trial, and use RWE to fill in evidential gaps to make the case for value.

Additionally, an alternative approach to appeal to payers and gain buy-in is to determine impact and have stakeholders align value end points to a meaningful time-to-impact horizon in order to determine true value.
3. MONITOR AND TRACK OUTCOMES TO INFORM ACTION (CONT.)

Because some disruptive therapeutics and diagnostics are durable and/or curative in nature, it is critical that longer periods of monitoring in clinical settings beyond the typical health plan focus are incorporated to prove value for each patient. 12-18 months does not have to be the default for medical value, and increasingly, has proven to fall short of the time it takes to see impactful clinical measures for patients with more complex and severe disease states.

Life science organizations partnering with payer groups should increasingly differentiate financial and clinical endpoints, and determine which endpoints are most beneficial to the individual and population-level total cost of care, compared to endpoints that only align with annual budgets and contracts.

**Typical value time-horizon for different types of payers**

<table>
<thead>
<tr>
<th>Temporary</th>
<th>Average</th>
<th>Long-term</th>
<th>Lifetime</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;12 months</td>
<td>12-18 months</td>
<td>2-5 years</td>
<td>5+ years</td>
</tr>
</tbody>
</table>

**PAYER PROFILE**

- State sponsored and operated
- Large national, Blues
- Regional not-for-profit, Blues
- Health system-sponsored health plan

**BUSINESS LINES**

- Public exchanges
- COBRA
- Medicaid (states with limited coverage)
- Employer-sponsored plans
- Employer-sponsored/individual plans in growing metro regions
- Medicaid (states with limited mobility; disability)
- Accountable care organizations
- Clinically integrated networks
- Medicare Advantage
- Rural/suburban provider-sponsored plans

---

Which value endpoints align with annual budgets and contracts?

Which value endpoints impact individual and population-level total cost of care?
3. MONITOR AND TRACK OUTCOMES TO INFORM ACTION (CONT.)

Questions for life sciences leaders to consider:

- How do payers evaluate a treatments’ long-term value when most of their covered patients only remain in-network for a limited time horizon?
- What metrics do payers use to evaluate whether a treatment will impact the downstream utilization of medical services?
- How does the integration of pharmaceutical and medical treatments (e.g., Car-T therapy) impact how payers make coverage choices?
- How do leaders leverage real-world data and convince regulators to be more comfortable with less-traditional sources of data?
- How can RWE help us overcome the mismatched time horizons of interest for us and other stakeholders?
- What new metrics do payer and provider stakeholders value for which evidence is scarce?
- What organizational model allows us to get the most value from our RWD assets?
Parting thoughts

Moving forward, life science organizations must continue to push the ecosystem to iterate and evolve on approaches to defining and paying for value. This change will require persistence and acknowledgement that:

- **Many organizations have not shifted their mindset about what constitutes as value, and novel therapies only further exacerbate this issue.** Life science leaders will have to consider how new innovations fit within the broader context of care delivery, and how multiple stakeholders working together can ensure that each patient has a holistic care journey. Life science organizations, payers and providers will need to work together to address tensions between population health needs and patient centricity, especially as more therapeutics and diagnostics become more personalized and precise.

- **Achieving medical value is hard, and multiple stakeholder incentives make accounting for it harder.** Multiple stakeholder incentives make defining time to impact difficult, however, life science organizations should be aligning time horizons to endpoints that best demonstrate value when working with multiple payer groups. Life science organizations will need to re-define the scope of assessment in order to avoid value misalignment and suboptimal metrics and data measurement.

- **Lastly, meaningful progress will require candid dialogue between leaders in industry, health care delivery, academic medicine, and patient advocacy groups.** The idea of a KOL is changing, and life science organizations should be taking a “ecosystem approach” to thinking about evidence circulation and influence. Abandoning the idea of identifying value in silos and working towards a shared understanding is the path forward.
Related content

Advisory Board resources

KEY TAKEAWAYS
Defining and assessing value for next-generation therapies
Read now

RESOURCE LIBRARY
Disruptive therapeutics and diagnostics cheat sheets
Read now

WEBINAR
How to drive provider success in value-based contracts
Read now

PODCAST
How do we define value? Here's what we learned from our cross-industry summit.
Read now
Evolving value to account for disruptive clinical products

Research lead
Fanta Cherif
fcherif@advisory.com
202-266-5421

Program leadership
Solomon Banjo

LEGAL CAVEAT

Advisory Board has made efforts to verify the accuracy of the information it provides to members. This report relies on data obtained from many sources, however, and Advisory Board cannot guarantee the accuracy of the information provided or any analysis based thereon. In addition, Advisory Board is not in the business of giving legal, medical, accounting, or other professional advice, and its reports should not be construed as professional advice. In particular, members should not rely on any legal commentary in this report as a basis for action, or assume that any tactics described herein would be permitted by applicable law or appropriate for a given member’s situation. Members are advised to consult with appropriate professionals concerning legal, medical, tax, or accounting issues, before implementing any of these tactics. Neither Advisory Board nor its officers, directors, trustees, employees, and agents shall be liable for any claims, liabilities, or expenses relating to (a) any errors or omissions in this report, whether caused by Advisory Board or any of its employees or agents, or sources or other third parties, (b) any recommendation or graded ranking by Advisory Board, or (c) failure of member and its employees and agents to abide by the terms set forth herein.

Advisory Board and the “A” logo are registered trademarks of The Advisory Board Company in the United States and other countries. Members are not permitted to use these trademarks, or any other trademark, product name, service name, trade name, and logo of Advisory Board without prior written consent of Advisory Board. All other trademarks, product names, service names, trade names, and logos used within these pages are the property of their respective holders. Use of other company trademarks, product names, service names, trade names, and logos or images of the same does not necessarily constitute (a) an endorsement by such company of Advisory Board and its products and services, or (b) an endorsement of the company or its products or services by Advisory Board. Advisory Board is not affiliated with any such company.

IMPORTANT: Please read the following.

Advisory Board has prepared this report for the exclusive use of its members. Each member acknowledges and agrees that this report and the information contained herein (collectively, the “Report”) are confidential and proprietary to Advisory Board. By accepting delivery of this Report, each member agrees to abide by the terms as stated herein, including the following:

1. Advisory Board owns all right, title, and interest in and to this Report. Except as stated herein, no right, license, permission, or interest of any kind in this Report is intended to be given, transferred to, or acquired by a member. Each member is authorized to use this Report only to the extent expressly authorized herein.

2. Each member shall not sell, license, republish, or post online or otherwise this Report, in part or in whole. Each member shall not disseminate or permit the use of, and shall take reasonable precautions to prevent such dissemination or use of, this Report by (a) any of its employees and agents (except as stated below), or (b) any third party.

3. Each member may make this Report available solely to those of its employees and agents who (a) are registered for the workshop or membership program of which this Report is a part, (b) require access to this Report in order to learn from the information described herein, and (c) agree not to disclose this Report to other employees or agents or any third party. Each member shall use, and shall ensure that its employees and agents use, this Report for its internal use only. Each member may make a limited number of copies, solely as adequate for use by its employees and agents in accordance with the terms herein.

4. Each member shall not remove from this Report any confidential markings, copyright notices, and/or other similar indicia herein.

5. Each member is responsible for any breach of its obligations as stated herein by any of its employees or agents.

6. If a member is unwilling to abide by any of the foregoing obligations, then such member shall promptly return this Report and all copies thereof to Advisory Board.